Opportunity Information: Apply for EP IDS 16 001
The Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator grant opportunity was designed to address a major gap in the U.S. and global response to antimicrobial resistance: there are not enough promising new antibacterial products moving through the early development pipeline. The federal government, building on the 2014 National Strategy for Combating Antimicrobial Resistant Bacteria, proposed a collaborative "accelerator" model to push candidate antibacterial products forward from proof-of-concept toward preclinical development. The core idea is to create a structured program that helps early-stage innovations mature into assets that are more attractive for later-stage private and public investment and, ultimately, clinical development.
This program is set up as a non-equity, non-dilutive accelerator. In practical terms, that means the accelerator would provide funding and support without taking ownership stakes in participating companies, allowing product developers to retain full control and ownership of their intellectual property and businesses. The accelerator concept mirrors approaches seen in the private sector, but with a government-backed structure intended to reduce early technical and financial risk in antibiotic development, an area that often struggles to attract sustained commercial investment due to scientific difficulty and uncertain returns.
The award mechanism is a cooperative agreement, reflecting that the government expects substantial involvement in shaping and supporting the work rather than simply providing funds with minimal interaction. The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response, would provide direct funding. The National Institute of Allergy and Infectious Diseases (NIAID) would contribute in-kind support such as access to preclinical services and technical expertise. The funded recipient would not simply run one research project; instead, the recipient would stand up and manage an accelerator program and oversee a portfolio of early-stage antibacterial product candidates, making investments and providing structured development support across multiple projects.
The program scope is explicitly limited to antibacterial products, rather than antivirals, antifungals, or broader antimicrobial technologies. The intent is to concentrate resources on bacterial threats where resistance is undermining standard treatments and where the early-stage pipeline is widely viewed as insufficient. By moving products through proof-of-concept and into and through preclinical development activities, the accelerator is meant to "graduate" projects that are positioned for subsequent R and D investment and entry into clinical trials.
Eligibility is broad and includes public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations with 501(c)(3) status (other than universities), for-profit organizations (including other than small businesses), small businesses, and other entities. Importantly, research institutions and non-domestic (non-U.S.) entities are also eligible, signaling an openness to drawing from global scientific and product-development capacity as long as applicants can meet the program and award requirements.
Funding details indicate a single expected award, with an award ceiling of $30,000,000. The opportunity falls under the Science and Technology and other Research and Development activity category and is listed under CFDA 93.360. The funding opportunity number is EP IDS 16 001, and the opportunity was created on February 17, 2016, with an original closing date of April 15, 2016. Because only one award was anticipated, applicants were effectively competing to become the cooperative agreement recipient that would operate the accelerator itself.
The application process included several mandatory screening requirements that functioned as hard gates; failing to meet them meant the application would not be reviewed. First, the full application had to be submitted electronically through grants.gov by April 15, 2016 at 11:59 PM EDT. Second, applicants were required to submit a letter of intent (LOI) by March 10, 2016 at 11:59 PM EST to the program office, addressed to Dr. Joseph Larsen (joseph.larsen@hhs.gov). The LOI needed to outline a project abstract and an approximate funding request, with additional instructions and a template referenced as Attachment F. Third, the program offered a pre-application workshop on March 3, 2016 (3:00 PM to 5:00 PM EST) at the Hubert H. Humphrey Building in Washington, DC, with an RSVP deadline of February 29, 2016 at 5:00 PM EST. The RSVP request required attendee details including names, titles, organizations, contact information, and country of citizenship. Fourth, a technical assistance conference call was scheduled for March 18, 2016 at 11:00 AM EST, but only for parties that had submitted an LOI. That call was intended to address application-process questions, and BARDA would respond to clarifying questions submitted with the LOI; call-in information would be provided only to LOI submitters.
Overall, the opportunity was less about funding a single lab effort and more about selecting an organization capable of building and running a national-level, government-supported antibacterial accelerator. The winning applicant would be expected to combine portfolio management, scientific and regulatory development strategy, and coordination with BARDA and NIAID resources to help multiple early-stage antibacterial candidates advance toward preclinical readiness and beyond.Apply for EP IDS 16 001
- The Assistant Secretary for Preparedness and Response in the science and technology and other research and development sector is offering a public funding opportunity titled "Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.360.
- This funding opportunity was created on 2016-02-17.
- Applicants must submit their applications by 2016-04-15. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $30,000,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Public and State controlled institutions of higher education, Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs) - CARB Biopharmaceutical Accelerator (EP IDS 16 001)
What is the CARB Biopharmaceutical Accelerator grant opportunity?
The Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator grant opportunity is a federal initiative designed to strengthen the early-stage pipeline for new antibacterial products. It targets a key gap in antimicrobial resistance (AMR) response: too few promising antibacterial candidates are moving from proof-of-concept into preclinical development.
What problem is this program trying to solve?
The program is intended to address the shortage of promising new antibacterial products in early development. Antibiotic R&D often faces scientific challenges and weak commercial incentives, which can limit investment. This accelerator model is intended to reduce early technical and financial risk so more candidates become viable for later-stage investment and clinical development.
Is this funding for a single research project or for running a program?
This opportunity is not structured as funding for a single laboratory research project. Instead, it is designed to select a recipient that will stand up, operate, and manage an accelerator program that oversees a portfolio of early-stage antibacterial product candidates.
What does "accelerator" mean in this funding opportunity?
In this context, an "accelerator" is a structured program intended to help early-stage antibacterial innovations mature. The accelerator would support candidate products as they move from proof-of-concept toward and through preclinical development, with the goal of graduating projects that are more attractive for later-stage public or private investment and eventual clinical development.
What does "non-equity, non-dilutive" mean here?
The accelerator is described as non-equity and non-dilutive, meaning it would provide funding and support without taking an ownership stake in participating companies. Product developers would retain ownership and control of their intellectual property and their businesses.
What award mechanism is used for this program?
The award mechanism is a cooperative agreement. This indicates the government expects substantial involvement in shaping and supporting the work, rather than providing funds with minimal interaction.
Which federal organizations are involved?
The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response, would provide direct funding. The National Institute of Allergy and Infectious Diseases (NIAID) would contribute in-kind support, such as access to preclinical services and technical expertise.
What kinds of products are in scope?
The scope is explicitly limited to antibacterial products. The opportunity is not described as covering antivirals, antifungals, or broader antimicrobial technologies.
What development stages does the accelerator focus on?
The accelerator is intended to push antibacterial candidates forward from proof-of-concept toward preclinical development, including advancing projects into and through preclinical development activities so they are positioned for subsequent R&D investment and entry into clinical trials.
Who is eligible to apply?
Eligibility is broad and includes: public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations with 501(c)(3) status (other than universities), for-profit organizations (including other than small businesses), small businesses, and other entities. Research institutions and non-domestic (non-U.S.) entities are also eligible.
Are non-U.S. organizations eligible to apply?
Yes. The opportunity states that non-domestic (non-U.S.) entities are eligible, indicating openness to global scientific and product-development capacity, provided applicants can meet program and award requirements.
How many awards were expected?
The funding details indicate a single expected award. Applicants were competing to become the cooperative agreement recipient that would operate the accelerator itself.
What is the maximum award amount?
The award ceiling is listed as $30,000,000.
What is the funding opportunity number and CFDA number?
The funding opportunity number is EP IDS 16 001. The opportunity is listed under CFDA 93.360.
When was the opportunity created and when did it close?
The opportunity was created on February 17, 2016. The original closing date for full applications was April 15, 2016.
How were applications submitted and what was the deadline?
Full applications had to be submitted electronically through grants.gov by April 15, 2016 at 11:59 PM EDT.
Was a Letter of Intent (LOI) required?
Yes. Submission of a Letter of Intent (LOI) was a mandatory screening requirement. If the LOI requirement was not met, the application would not be reviewed.
When was the LOI due and what did it need to include?
The LOI was due by March 10, 2016 at 11:59 PM EST. It needed to outline a project abstract and an approximate funding request. Additional instructions and a template were referenced as Attachment F.
Where was the LOI sent and who was the point of contact?
The LOI had to be submitted to the program office and addressed to Dr. Joseph Larsen at joseph.larsen@hhs.gov.
What were the "mandatory screening requirements" and why do they matter?
The opportunity described several hard-gate screening requirements (including on-time electronic submission through grants.gov and submission of the LOI by the stated deadline). These requirements mattered because failure to meet them meant the application would not be reviewed.
Was there a pre-application workshop?
Yes. A pre-application workshop was offered on March 3, 2016 from 3:00 PM to 5:00 PM EST at the Hubert H. Humphrey Building in Washington, DC.
How did applicants RSVP for the pre-application workshop?
The RSVP deadline was February 29, 2016 at 5:00 PM EST. The RSVP request required attendee details including names, titles, organizations, contact information, and country of citizenship.
Was technical assistance available to applicants?
Yes. A technical assistance conference call was scheduled for March 18, 2016 at 11:00 AM EST to address application-process questions.
Who could join the technical assistance call?
The technical assistance call was only for parties that had submitted an LOI. Call-in information would be provided only to LOI submitters.
How were applicant questions handled for the technical assistance call?
BARDA would respond to clarifying questions that were submitted with the LOI. The technical assistance call was intended to address questions about the application process.
What is the main responsibility of the selected recipient?
The selected recipient would be expected to build and run a government-supported antibacterial accelerator, oversee a portfolio of early-stage antibacterial candidates, make investments and provide structured development support across multiple projects, and coordinate with BARDA and NIAID resources.
How does this program relate to national AMR strategy?
The accelerator model builds on the 2014 National Strategy for Combating Antimicrobial Resistant Bacteria, aligning with federal efforts to strengthen antibacterial development as resistance undermines standard treatments.
What activity category is this opportunity listed under?
The opportunity falls under the Science and Technology and other Research and Development activity category.
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: Limited Competition for Cooperative Agreements to Support Navigators in Federally-facilitated and State Partnership Marketplaces
Previous opportunity: FY16 FDPNE Projects
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for EP IDS 16 001
Applicants also applied for:
Applicants who have applied for this opportunity (EP IDS 16 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| Domestic Nuclear Detection Office: Academic Research Initiative (ARI Apply for DHS 16 DNDO 077 001 Funding Number: DHS 16 DNDO 077 001 Agency: Office of Procurement Operations - Grants Division Category: Science and Technology and other Research and Development Funding Amount: $3,250,000 |
| Spinal Cord Injury Model Systems Apply for HHS 2016 ACL NIDILRR SI 0158 Funding Number: HHS 2016 ACL NIDILRR SI 0158 Agency: Administration for Community Living Category: Science and Technology and other Research and Development Funding Amount: $484,000 |
| Field Biology Technical Assistance and Predator Control for Pacific Missile Range Facility (PMRF), Kauai, Hawaii Apply for W9126G 24 2 SOI 2518 Funding Number: W9126G 24 2 SOI 2518 Agency: Department of Defense Category: Science and Technology and other Research and Development Funding Amount: $3,249,191 |
| Research Training Groups in the Mathematical Sciences Apply for 24 570 Funding Number: 24 570 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $600,000 |
| Fiscal Year (FY) 2024 National Science Portal (NSP) Apply for FOAAFRLAFOSR20240008 Funding Number: FOAAFRLAFOSR20240008 Agency: Air Force Office of Scientific Research Category: Science and Technology and other Research and Development Funding Amount: $4,500,000 |
| Integrated Training Area Management (ITAM) Support TRADOC Proponent Office (TPO) Ranges Apply for W9126G 24 2 SOI 2233 Funding Number: W9126G 24 2 SOI 2233 Agency: Fort Worth District Category: Science and Technology and other Research and Development Funding Amount: $3,552,204 |
| Natural Resources Support – Plover Audio Monitoring at Vandenberg SFB, CA Apply for W9126G 24 2 SOI 2875 Funding Number: W9126G 24 2 SOI 2875 Agency: Fort Worth District Category: Science and Technology and other Research and Development Funding Amount: $137,970 |
| NIJ FY24 Invited to Apply - Safe Transitions for Teens: Assessing the Impact of Intimate Partner Transitional Housing on Adolescent Residents Study Apply for O NIJ 2024 172130 Funding Number: O NIJ 2024 172130 Agency: National Institute of Justice Category: Science and Technology and other Research and Development Funding Amount: $842,337 |
| Natural Resources Support - Black Abalone at Vandenberg SFB, California Apply for W9126G 24 2 SOI 2874 Funding Number: W9126G 24 2 SOI 2874 Agency: Fort Worth District Category: Science and Technology and other Research and Development Funding Amount: $331,650 |
| Bat Surveys Support at Belle Fountain Area Ditches 1 & 2, Pemiscot, MO and 15 Mile Bayou in Edmondson, AR Apply for W9126G 24 2 SOI 2890 Funding Number: W9126G 24 2 SOI 2890 Agency: Fort Worth District Category: Science and Technology and other Research and Development Funding Amount: $140,000 |
| SCI Botany Implementation, San Clemente Island, CA Apply for W9126G 24 2 SOI 2856 Funding Number: W9126G 24 2 SOI 2856 Agency: Fort Worth District Category: Science and Technology and other Research and Development Funding Amount: $2,364,933 |
| Advance Research Collaboration Through C-SIPA Apply for DOS MANAMA PD 2024 003 Funding Number: DOS MANAMA PD 2024 003 Agency: U.S. Mission to Bahrain Category: Science and Technology and other Research and Development Funding Amount: $60,000 |
| ProCON Global Apply for DFOP0016574 Funding Number: DFOP0016574 Agency: Bureau of Cyberspace and Digital Policy Category: Science and Technology and other Research and Development Funding Amount: $10,000,000 |
| Global Information and Communications Technology (ICT) and Critical and Emerging Technology (CET) Standards Apply for DFOP0016578 Funding Number: DFOP0016578 Agency: Bureau of Cyberspace and Digital Policy Category: Science and Technology and other Research and Development Funding Amount: $2,250,000 |
| Global Emerging Leaders in International Cyberspace Security (GEL-ICS) Apply for DFOP0016603 Funding Number: DFOP0016603 Agency: Bureau of Cyberspace and Digital Policy Category: Science and Technology and other Research and Development Funding Amount: $900,000 |
| National STEM Teacher Corps Pilot Program Apply for 24 577 Funding Number: 24 577 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $10,000,000 |
| UTILIZING PUBLIC - PRIVATE PARTNERSHIPS TO ADVANCE TIPPING POINT TECHNOLOGIES Apply for NNH16ZOA001N 16STMD 001 Funding Number: NNH16ZOA001N 16STMD 001 Agency: NASA Headquarters Category: Science and Technology and other Research and Development Funding Amount: $2,500,000 |
| Funding Opportunity Announcement from the Office of Naval Research (ONR) Navy and Marine Corps FY2016 for the HEL-JTO High Energy Laser Multidisciplinary Research Initiative (HEL-MRI) Program Apply for N00014 16 R FO13 Funding Number: N00014 16 R FO13 Agency: Office of Naval Research Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| ULTRA-HIGH BYPASS (UHB) ADVANCED NACELLE TECHNOLOGIES FLIGHT DEMONSTRATION Apply for NNL16ZD3001C Funding Number: NNL16ZD3001C Agency: NASA Headquarters Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Local STEM High School Research and Development (R&D) Apply for FOA AFRL RQKP 2016 0002 Funding Number: FOA AFRL RQKP 2016 0002 Agency: Air Force -- Research Lab Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "EP IDS 16 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.